Wegovy®
Wegovy® (semaglutide 2.4mg) — FDA-approved for chronic weight management. Average 15% body weight loss. Online physician evaluation, same-day prescription, all 50 states.
Prescription required. Provider determines clinical appropriateness.
Wegovy® (semaglutide 2.4mg) — FDA-approved weight management
Wegovy® is semaglutide 2.4mg, a GLP-1 receptor agonist FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Clinical trials showed average weight loss of about 15% of body weight over 68 weeks. Administered as a once-weekly subcutaneous self-injection in the abdomen, thigh, or upper arm. The FirstCall platform connects you with an independent, board-certified physician for evaluation and, when clinically appropriate, a prescription sent to a pharmacy of your choice.
semaglutide 2.4mg
once-weekly subcutaneous injection (pre-filled auto-injector pen)
~15% of body weight over 68 weeks (clinical trial average)
Educational content. Last clinically reviewed by the FirstCall Clinical Editorial Board, June 2026. The FirstCall platform provides access to independent, licensed physicians; final clinical decisions rest with the prescribing physician. Seek emergency care for severe abdominal pain (possible pancreatitis), severe allergic reaction, or signs of gallbladder problems.
What is semaglutide (Wegovy®)?
Wegovy® is semaglutide 2.4mg — a GLP-1 receptor agonist developed and FDA-approved specifically for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition. Semaglutide mimics the GLP-1 hormone released after eating, suppressing appetite, slowing gastric emptying, and improving insulin sensitivity. In the pivotal STEP trials, participants lost an average of 15% of body weight over 68 weeks — the largest clinical weight loss result seen with any medication at the time of approval.
Comparing options: Wegovy® and Ozempic® both contain semaglutide, but they are different products. Ozempic® is FDA-approved for type 2 diabetes management at a maximum 1mg dose. Wegovy® is approved specifically for weight loss at the higher 2.4mg dose. FirstCall prescribes the appropriate product based on your clinical indication.
What to expect on Wegovy®
Clinical trial averages — individual results vary.
GLP-1 suppression begins reducing hunger. Most patients notice significantly smaller appetite within 2–4 weeks.
Average loss at 3 months with consistent treatment alongside diet and exercise.
Significant body composition changes. Metabolic markers improving.
Maximum average benefit in clinical trials. Maintained with continued treatment.
Who qualifies for Wegovy®?
FDA approval covers adults with BMI 30+ (obesity) or BMI 27+ (overweight) with at least one weight-related condition such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. The physician you're connected with will assess eligibility and whether Wegovy® or another GLP-1 medication is most appropriate for your profile.
The physician you're connected with will assess eligibility and help navigate insurance or cash-pay options at your free consultation.
How to get Wegovy® through FirstCall
Brief health intake including BMI, health history, and current medications. Free. Takes about 10 minutes.
Physician evaluates eligibility and assists with prior authorization or advises on cash-pay options.
Prescription issued. Ongoing physician access for dose escalation, side effect management, and progress review.
Frequently asked questions
Everything you need to know about Wegovy® and how FirstCall works.
Wegovy® is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use during pregnancy — discontinue at least 2 months before attempting conception. Common side effects include nausea, vomiting, diarrhea, and constipation during dose escalation. Pancreatitis has been reported — seek immediate care for severe abdominal pain. Gallbladder disease risk is increased.
Other GLP-1 options
Your physician will recommend the most appropriate medication for your profile.
